It has rapid absorption and a duration of action of about 6 h, since microspheres reach the lung alveoli and dissolve at physiological pH [178] The efficacy observed in clinical studies and the favorable pulmonary safety profile allowed exubera to be the first inhaled insulin approved in 2006 for use in adult patients with diabetes mellitus in the USA and Europe. This evidence concerns the gene INS and diabetes mellitus.